Anthera Pharmaceuticals, Inc.
ANTH · OTC
12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | -95.4% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | $0 | $0 | -$0 |
| % Margin | – | 68.1% | 99% | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -39,432.4% | -1,106.5% | – |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | -$0 | -$0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -36,967.6% | -1,096.1% | – |
| EPS | -1.65 | -10.38 | -7.84 | -11.13 |
| % Growth | 84.1% | -32.4% | 29.6% | – |
| EPS Diluted | -1.65 | -10.38 | -7.84 | -11.13 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | -$0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | -39,249% | -1,097.6% | – |